A Phase 1, Randomized, Placebo-Controlled Single-Blind, Dose-Ranging, 4-Way Crossover Study to Evaluate the Effect of Different Fixed Pramlintide: Insulin Dose Ratios on Postprandial Glycaemic Control in Subjects With Type 1 Diabetes Mellitus

Trial Profile

A Phase 1, Randomized, Placebo-Controlled Single-Blind, Dose-Ranging, 4-Way Crossover Study to Evaluate the Effect of Different Fixed Pramlintide: Insulin Dose Ratios on Postprandial Glycaemic Control in Subjects With Type 1 Diabetes Mellitus

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Oct 2014

At a glance

  • Drugs Pramlintide (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Amylin Pharmaceuticals; AstraZeneca
  • Most Recent Events

    • 19 Oct 2014 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
    • 17 Sep 2014 Results presented at the 50th Annual Meeting of the European Association for the Study of Diabetes.
    • 08 Nov 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top